We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Brand Companies Fight Against Calls for Flexible Biosimilars Regulations
Brand Companies Fight Against Calls for Flexible Biosimilars Regulations
November 5, 2010
Brand-drug makers are putting up a unified front in their efforts to ensure strict limits on the development of biosimilars, telling the FDA that regulation of the drugs should be much tighter than that being sought by generic manufacturers.